Waverley Pharma (5GZ) Stock Statistics & Valuation Metrics
Total Valuation
Waverley Pharma has a market cap or net worth of EUR 345.98K. The enterprise value is EUR 4.91M.
- Market Cap
- EUR 345.98K
- Enterprise Value
- EUR 4.91M
Share Statistics
Waverley Pharma has 54,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Waverley Pharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, Waverley Pharma had revenue of ― and earned -1,078 in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- ―
- Operating Income
- -1,078
- Pretax Income
- ―
- Net Income
- -1,078
- EBITDA
- -1,078
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- -0.08
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Waverley Pharma upcoming earnings date is Nov 20, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Nov 20, 2026
- Ex-Dividend Date
- ―
Balance Sheet
Waverley Pharma has ― in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- EUR 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for Waverley Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- -11.52%
- EPS Growth Forecast
- -70.00%
